Effects of nucleic acid polymer therapy alone or in combination with immunotherapy on the establishment of SVR in patients with chronic HBV infection.

**Background**

Nucleic acid polymers (NAPs) block HBsAg release from infected hepatocytes, a novel approach to clear serum HBsAg in human patients. Three proof of concept clinical trials examined tolerability and antiviral effects of NAPs in Asian patients with chronic, HBeAg+ HBV infection in monotherapy or in combination with immunotherapy. Follow-up data from these studies is herein reported.

**Methods**

IRB approved, open label trials (REP 101, 102 and 201) were conducted in Bangladesh with no stratification or randomization. Treatment naive patients > 18 years old with chronic HBV infection (HBV DNA > 10^5 copies / ml, evidence of liver fibrosis and ALT < 5X ULN) were eligible. All patients except one were HBeAg+. NAPs were administered by intravenous infusion (400mg qW for REP 2055, 500mg qW for REP 2139-Ca). Pegasys® (180ug qW) or Zadaxin® (1.6mg 2qW) were administered by subcutaneous injection. Entecavir (ETV) was dosed orally qD (0.5mg).

Primary efficacy outcomes are identified in the table below and were determined using accepted test platforms (Roche LLOQ). Evidence of liver fibrosis and ALT < 5X ULN were eligible. All patients except one were HBeAg+. NAPs were administered by intravenous infusion (400mg qW for REP 2055, 500mg qW for REP 2139-Ca). Pegasys® (180ug qW) or Zadaxin® (1.6mg 2qW) were administered by subcutaneous injection. Entecavir (ETV) was dosed orally qD (0.5mg).

**Contact:** availlant@replicor.com

---

**SVR data and conclusions**

**REP 101 trial**

REP 2055 monotherapy

**REP 102 trial**

REP 2139-Ca + partial immunotherapy

**REP 201 trial**

REP 2139-Ca + Pegasys® + ETV

**NAP-induced clearance of serum HBsAg (on treatment dynamics)**

**HBsAg clearance permits restoration of functional anti-HBs response (on treatment dynamics)**

**NAP-induced clearance of serum HBV DNA**

---

Contact: availlant@replicor.com
Effects of nucleic acid polymer therapy alone or in combination with immunotherapy on the establishment of SVR in patients with chronic HBV infection.

Mamun-Al-Mahtab1, Michel Bazinet2 and Andrew Vaillant2

1Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh, 2REPLICor Inc., Montreal, Canada H8Y 3E6

<table>
<thead>
<tr>
<th>Trial</th>
<th>REP 101 protocol</th>
<th>REP 102 protocol</th>
<th>REP 201 protocol</th>
</tr>
</thead>
<tbody>
<tr>
<td>Treatment</td>
<td>REP 2055</td>
<td>REP 2139-Ca + 13-26 weeks Pegasys® and / or Zadaxin®</td>
<td>REP 2139-Ca + 48 weeks Pegasys™ (+ ETV in 2 patients)</td>
</tr>
<tr>
<td>Patients enrolled</td>
<td>8</td>
<td>12</td>
<td>5</td>
</tr>
<tr>
<td>Patients with HBsAg reduction or clearance</td>
<td>7</td>
<td>10</td>
<td>5</td>
</tr>
<tr>
<td>Patients receiving immunotherapy</td>
<td>0</td>
<td>9</td>
<td>5</td>
</tr>
<tr>
<td>Patients with short term (~3 M) SVR* off treatment</td>
<td>3</td>
<td>8</td>
<td>4</td>
</tr>
<tr>
<td>Patients with long term SVR* (&gt; 12 months)</td>
<td>2</td>
<td>4</td>
<td>4</td>
</tr>
</tbody>
</table>

* serum HBV DNA < 500 CPM

CONCLUSIONS

• NAP therapy in combination with immunotherapy and ETV appears safe
• Combining REP 2139-Ca and immunotherapy has a synergistic antiviral effect (immunostimulation in the absence of HBsAg).
• NAP-based combination therapy may substantially increase the SVR rate compared to existing treatments for chronic hepatitis B infection